The US District Court for the Northern District of Illinois dismisses antitrust case challenging patent thicket (Humira)

On June 8, 2020, the U.S. District Court for the Northern District of Illinois granted defendants’ motion to dismiss an antitrust case challenging behavior arising out of a massive collection of patents known as a “patent thicket.” In re Humira (Adalimumab) Antitrust Litigation, 2020 WL 3051309 (N.D. Ill. June 8, 2020). The court dismissed claims that such conduct constituted monopolizing sham behavior, included illegal settlements, and caused anticompetitive harm. Background Humira is an “anti-inflammatory biologic,” which is “a drug derived from living organisms that helps slow down overactive immune systems.” Id. at *2. Originally developed to treat rheumatoid arthritis, Humira “is now used to treat a variety of auto-immune disorders ranging from Crohn’s disease to plaque psoriasis.” Id.

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The US District Court for the Northern District of Illinois dismisses antitrust case challenging patent thicket (Humira), 8 juin 2020, e-Competitions June 2020, Art. N° 96364

Visites 73

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues